GPR107
Protein GPR107
Also known as: FLJ20998, GP107_HUMAN, KIAA1624, LUSTR1, RP11-88G17
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q5VW38
- Gene
- GPR107
- Ensembl
- ENSG00000148358
- Chromosome
- 9
- Canonical length
- 600 aa
- Protein class
- Predicted membrane proteins, Transporters
- Subcellular location
- Nucleoplasm,Golgi apparatus
OverviewNCBI Gene
Predicted to enable clathrin heavy chain binding activity. Predicted to be involved in clathrin-dependent endocytosis. Located in Golgi apparatus and nucleoplasm. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
600 residues, UniProt reviewed canonical sequence.
>Q5VW38|GPR107
1 MAALAPVGSP ASRGPRLAAG LRLLPMLGLL QLLAEPGLGR VHHLALKDDV RHKVHLNTFG
61 FFKDGYMVVN VSSLSLNEPE DKDVTIGFSL DRTKNDGFSS YLDEDVNYCI LKKQSVSVTL
121 LILDISRSEV RVKSPPEAGT QLPKIIFSRD EKVLGQSQEP NVNPASAGNQ TQKTQDGGKS
181 KRSTVDSKAM GEKSFSVHNN GGAVSFQFFF NISTDDQEGL YSLYFHKCLG KELPSDKFTF
241 SLDIEITEKN PDSYLSAGEI PLPKLYISMA FFFFLSGTIW IHILRKRRND VFKIHWLMAA
301 LPFTKSLSLV FHAIDYHYIS SQGFPIEGWA VVYYITHLLK GALLFITIAL IGTGWAFIKH
361 ILSDKDKKIF MIVIPLQVLA NVAYIIIEST EEGTTEYGLW KDSLFLVDLL CCGAILFPVV
421 WSIRHLQEAS ATDGKGDSMG PLQQRANLRA GSRIESHHFA QADLELLASS CPPASVSQRA
481 GITAAINLAK LKLFRHYYVL IVCYIYFTRI IAFLLKLAVP FQWKWLYQLL DETATLVFFV
541 LTGYKFRPAS DNPYLQLSQE EEDLEMESVV TTSGVMESMK KVKKVTNGSV EPQGEWEGAVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GPR107 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.37
- Highest tissue expression
- 33 nTPM
Expression across tissuesHPA
Tissue
- thyroid gland: 33 nTPM
- parathyroid gland: 27 nTPM
- retina: 24 nTPM
- blood vessel: 24 nTPM
- prostate: 22 nTPM
- choroid plexus: 22 nTPM
Single-cell type
- neutrophils: 152 nCPM
- cardiomyocytes: 94 nCPM
- choroid plexus epithelial cells: 91 nCPM
- retinal pigment epithelial cells: 90 nCPM
- myonuclei: 86 nCPM
- syncytiotrophoblasts: 81 nCPM
Immune cell
- non-classical monocyte: 3.6 nTPM
- intermediate monocyte: 3.4 nTPM
- neutrophil: 3.1 nTPM
- classical monocyte: 2.8 nTPM
- eosinophil: 1.9 nTPM
- myeloid DC: 1.8 nTPM
Brain region
- pons: 46 nTPM
- midbrain: 46 nTPM
- choroid plexus: 43 nTPM
- hypothalamus: 42 nTPM
- medulla oblongata: 42 nTPM
- thalamus: 41 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.42
- gnomAD pLI
- 0.29
- gnomAD missense Z
- 1.82
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GPR107 as an antibody target. Whether an autoantibody or antibody against GPR107 could matter depends on whether native GPR107 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GPR107 is annotated at the cell surface, where native GPR107 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label GPR107 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...